T reatment with dual antiplatelet therapy (DAPT) after an episode of acute coronary syndrome has demonstrated efficacy in reducing subsequent major adverse cardiovascular events (MACEs), 1-3 but recent trials have shown conflicting results regarding the optimal adenosine diphosphate receptor inhibitor (ADPri) treatment duration after coronary stenting. Results from the ISAR-SAFE study (Safety and Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting) supported shorter durations of ADPri therapy, whereas the DAPT and PEGASUS-TIMI 54
trials (Prevention of Cardiovascular Events in Patients With
Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) indicated that there are benefits to longer ADPri treatment durations. [4] [5] [6] [7] [8] Current myocardial infarction (MI) guidelines provide a class I recommendation for all MI patients for 12 months of ADPri treatment along with aspirin therapy and at least 12 months of ADPri treatment for those with a drug-eluting stent (DES). [9] [10] [11] [12] Nevertheless, early clopidogrel cessation has been previously observed, [13] [14] [15] [16] [17] [18] and these discontinuation decisions are reflective of both patients and providers. 19 To optimize long-term patient outcomes, we need to better understand the prevalence of ADPri cessation, as well as the factors associated with cessation in community practice.
The TRANSLATE-ACS study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) examined a large contemporary cohort of ST-segment-elevation myocardial infarction (STEMI) and non-STEMI patients discharged after percutaneous coronary intervention (PCI) on ADPri therapy. TRANSLATE-ACS was a longitudinal registry that included contemporary patients treated with either clopidogrel or a higher potency ADPri and captured patientreported reasons for ADPri cessation. As a result, this registry affords a unique perspective of antiplatelet adherence patterns in routine practice. The objectives of our analysis were to (1) determine the frequency with which patients discontinued ADPri earlier than 1 year; (2) assess whether early, first-time cessation rates varied by type of stent placed or type of ADPri agent prescribed at discharge; and (3) examine the association of early, first-time ADPri cessation with risk of downstream MACE.
Methods

Study Population
TRANSLATE-ACS was an observational study (http://www. clinicaltrials.gov: NCT01088503) of contemporary acute MI patients treated with PCI and an ADPri during their index hospitalization at 1 of 233 participating hospitals in the United States. The study rationale and design have been previously described in detail. 20 Enrollment was broadly inclusive, excluding only patients who were unable or unwilling to provide written consent for follow-up or were participating in another research study that directed the use of either an investigational or approved ADPri within the first 12 months post-MI. Participation in TRANSLATE-ACS was approved by the institutional review board of each hospital, and each patient provided written informed consent before enrollment. All treatment decisions were made by the treating physicians in accordance with practice guideline recommendations and local standards of care and practice. Patients were enrolled between April 4, 2010, and October 31, 2012. Patients were excluded if they died during the index hospitalization (n=14), if they were not discharged on an ADPri after the index hospitalization (n=66), or if there was missing information on ADPri use at any of the follow-up interviews (n=289).
Data Collection and Definitions
Characteristics of the index hospitalization, including baseline demographics, clinical characteristics, processes of care, and in-hospital outcomes, were collected using standardized data elements adapted from the National Cardiovascular Data Registry CathPCI Registry. 21, 22 After discharge from their index hospitalization, patients were interviewed via telephone at 6 weeks, 6 months, 12 months, and 15 months by trained personnel from the Duke Clinical Research Institute (Durham, NC). During each interview, patients were asked to provide a list of all current medications, including ADPris (ie, clopidogrel, prasugrel, ticlopidine, and ticagrelor). If the patient was observed to no longer be on an ADPri, then the date and reason for discontinuation were queried. Patients were also asked if their ADPri was temporarily discontinued; if so, they were asked to indicate the duration of interruption.
Early first-time cessation of ADPri therapy was defined as any >7day gap in treatment within the 1-year postdischarge. By the seventh day of gap in treatment, the patient was classified as off-treatment and contributed to the analysis accordingly until treatment was reinitiated. Patients who switched from one ADPri to another were not included in the cessation group. We divided ADPri cessation into 5 groups based on the following patient-reported reasons for cessation; these reasons were adapted from the PARIS study (Patterns of Non-Adherence to Dual Anti-Platelet Regimen in Stented Patients) 5 : (1) discontinuation: stopped because the healthcare provider felt ADPri was no longer needed and switched to another non-ADPri antiplatelet medication; (2) interruption: a ≥7-day gap in ADPri therapy because of a surgical operation or procedure; (3) disruption because of side effects: a ≥7-day gap in ADPri therapy because of medication side effects, including bleeding or severe bruising; (4) disruption because of patient factors: a ≥7-day gap in ADPri therapy because the patient elected not to refill when the prescription ran out, the medication cost too much, the patient felt it was not helping, or the patient was advised by family or friends to stop; and (5) disruption because of unknown factors: patient reported a reason other than the above or the patient did not know the reason for treatment cessation. If a patient indicated multiple reasons, then the patient was grouped according to the following hierarchy: discontinuation over interruption over disruption.
MACE was defined as the composite of all-cause death, recurrent MI, stroke, or unplanned coronary revascularization during the 1-year postdischarge. Events were independently validated by study physicians based on review of associated hospital bills and medical records using protocol-defined criteria. 20 We also performed a sensitivity analysis, where we examined an alternative definition of MACE that excluded unplanned revascularization.
WhAT IS KNOWN
• Guidelines recommend the use of adenosine diphosphate receptor inhibitor therapy for 1 year after acute myocardial infarction.
• Recent trials have shown conflicting results regarding the optimal adenosine diphosphate receptor inhibitor treatment duration after coronary stenting.
• Early cessation of therapy occurs frequently in clinical practice.
WhAT ThE STUDY ADDS
• We found that 1 in 5 myocardial infarction patients stopped adenosine diphosphate receptor inhibitor treatment within 1 year of percutaneous coronary intervention.
• Most often (50%), adenosine diphosphate receptor inhibitor treatment was stopped because the healthcare provider suggested to do so; ≈1 in 5 patients stopped treatment themselves without consulting a physician.
• Early cessation was associated with increased risk of major adverse cardiovascular events. Early ADPri Cessation
Statistical Analyses
Univariable comparisons were made between patients who did and did not have ADPri cessation by 12 months postdischarge and by cessation reason among those who stopped ADPri. Categorical variables were summarized by count and percentages and compared using the Pearson χ 2 test. Continuous variables were summarized by means, standard deviation, and median (25th, 75th percentiles). Kruskal-Wallis tests and Wilcoxon rank-sum tests were used to compare reasons for cessation and whether or not patients stopped ADPri, respectively.
We examined time to ADPri cessation using Kaplan-Meier methods stratified by discharge ADPri type (prasugrel versus clopidogrel) and by stent type (DES versus bare metal stent [BMS]). If a patient received both DES and BMS, then the patient was categorized as treated with DES. Unadjusted and adjusted Cox proportional hazards models were used to assess the association of ADPri cessation within 12 months with ADPri drug and stent type, expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). Schoenfeld residuals were used to assess the proportional hazards assumption. Follow-up began on the date of discharge and ended at: (1) ADPri cessation date (first day of a gap ≥7 days); (2) 365 days after discharge; or (3) date of death or date last known alive. The following variables were included in the multivariable models: age, sex, race (white versus nonwhite), insurance (private versus government versus other), marital status, employment status, previous MI, previous PCI, previous coronary artery bypass graft surgery, previous heart failure, previous stroke or transient ischemic attack, peripheral artery disease, diabetes mellitus, hypertension, current tobacco use, gastrointestinal or genitourinary bleeding within the last 6 months, MI type (STEMI versus non-STEMI), body mass index, home oral anticoagulant use, home ADPri use, home aspirin use, extent of coronary disease (3-versus 2-versus 1-vessel), multivessel PCI, culprit lesion in graft, culprit lesion previously treated, culprit lesion length, any DES used, ejection fraction ≤40%, postprocedure hemoglobin, preprocedure creatinine, EuroQol-5 dimension index, and in-hospital major bleeding event. Finally, we performed unadjusted and adjusted Cox proportional hazards modeling to examine the association of ADPri cessation with MACE. ADPri cessation was modeled as a binary time-varying covariate. Therefore, patients could change exposure groups (on-versus off-treatment) according to time throughout follow-up. The date of discharge was defined as time 0. This was also performed separately by discharge ADPri and stent type. To examine the association of cessation reason and MACE, a time-varying covariate was modeled for each cessation 
Results
Among 11 858 acute MI patients discharged alive on ADPri therapy after PCI, 2514 (21.2%) stopped ADPri therapy earlier than the guideline-recommended course of 1 year. The median time from discharge to ADPri cessation for these patients was 200.5 days (25th, 75th percentiles: 71, 340). As shown in Table 1 , the distribution of age, sex, and race was similar between groups; however, patients who stopped ADPri therapy early were less likely to be used or to have health insurance than those who were still on an ADPri at 1 year. The prevalence of previous MI, previous coronary revascularization (either PCI or coronary artery bypass graft surgery), previous heart failure, diabetes mellitus, and dyslipidemia was higher among patients who were still on ADPri therapy at 1 year post-MI. Patients who discontinued ADPri within 1 year were less likely to have undergone multivessel PCI than those who were still on ADPri therapy at 1 year post-MI. In-hospital MACE rates were not significantly different between groups. An oral anticoagulant was prescribed at discharge for 7.7% of patients who discontinued ADPri within 1 year and 4.7% of patients still on ADPri therapy 1 year post-MI (P<0.0001).
Cessation of ADPri Therapy by Discharge ADPri and Stent Type
At discharge, 3439 (29.0%) and 8107 (68.4%) patients were prescribed prasugrel and clopidogrel, respectively. By 1 year postdischarge, 23.2% of patients discharged on prasugrel had stopped ADPri therapy compared with 21.0% of patients discharged on clopidogrel (P=0.03). Nonetheless, among patients who stopped ADPri therapy within the first year, those discharged on prasugrel stayed on ADPri therapy significantly longer than those discharged on clopidogrel; the median time from discharge to ADPri cessation was 251.5 days (25th, 75th percentiles: 83, 350) for prasugrel and 188.0 days (25th, 75th percentiles: 66, 334) for clopidogrel. After multivariable adjustment, prasugrel use was associated with a greater likelihood of early cessation compared with clopidogrel (adjusted HR, 1.28; 95% CI, 1.17-1.40; P<0.0001).
DES were implanted in 53.9% of patients who had stopped ADPri therapy by 1 year; 33.3% of these patients stopped ADPri within 6 months post-MI. As shown in Figure 1 , although ADPri cessation rates steadily increased during the first 12 months postdischarge for patients treated with DES, there was an abrupt increase in ADPri cessation rate around 30 days postdischarge among patients treated with BMS. After the 30-day mark, a steady but more rapid rate of cessation was observed for BMS-treated than for DEStreated patients. Among patients who stopped ADPri early, the median time from discharge to cessation was 301 days (25th, 75th: 137, 353) for DES versus 121 days (25th, 75th: 39, 268) for BMS. Among patients who received DES, 1349 (16%) stopped ADPri before 12 months postdischarge versus 1073 (35.2%) BMS recipients. In the multivariable model, DES was associated with a significantly lower rate of ADPri cessation (adjusted HR, 0.40; 95% CI, 0.37-0.44; P<0.0001) compared with BMS.
Reasons for Cessation of ADPri Therapy
Patient-reported reasons for ADPri cessation within the first year post-MI are shown in Figure 2 . The most frequent patientreported reason for ADPri cessation was per healthcare provider recommendation (54% of all early ADPri cessation). Disruption because of patient factors (eg, cost) was the second most common reason, accounting for 19% of ADPri cessation within the first year post-MI. Only 9% stopped ADPri early because of medication side effects and 10% because of surgical procedures. Table 2 displays the distribution of cessation reasons, stratified by discharge ADPri and stent types. Patient characteristics according to cessation reason are shown in Table 3 . Patients who reported treatment disruption because of patient factors were younger and less likely to have health insurance (despite having a greater likelihood of employment), be married, or have graduated from high school compared with patients who stopped treatment for other reasons.
Patients with clinician-directed early ADPri discontinuation were less likely to have cardiovascular risk factors compared with patients who had treatment cessation for other reasons.
ADPri Cessation and Associated Outcomes
MACE occurred in 14.5% of patients who had ADPri cessation within the first year post-MI and in 13.7% of patients who continued ADPri therapy to 1 year. ADPri cessation was associated with an increased unadjusted risk of MACE (HR, 1.63; 95% CI, 1.39-1.90) that persisted after multivariable adjustment (HR, 1.40; 95% CI, 1.19-1.65). The relationship between ADPri cessation and MACE was similar when stratified by discharge treatment clopidogrel versus prasugrel use (Figure 3 ). Nevertheless, ADPri cessation within 1 year post-MI was associated with increased MACE risk among DES-treated patients (adjusted HR, 1.95; 95% CI, 1.53-2.49; P≤0.0001) but not among BMS-treated patients (adjusted HR, 1.07; 95% CI, 0.85-1.34; P=0.58). As mentioned previously, we performed a sensitivity analysis, where we examined an alternative definition of MACE that excluded unplanned revascularization. The results of this analysis were similar to the primary analyses of the MACE ( Table I in the Data  Supplement) . Table 4 shows the relationship between reason for ADPri cessation and MACE at 1 year. Compared with patients who continued on ADPri therapy, those who discontinued ADPri use per a healthcare provider did not have an increased risk of MACE after adjustment; this was also true for patients who stopped ADPri therapy early because of patient-related or unknown factors. In contrast, cessation because of interruption or medication side effects was associated with a higher risk of MACE. In a secondary analysis, where disruption because of medication side effects and patient choice were combined, we again observed an increased risk of MACE with interruption (HR, 2.89; 95% CI, 2.04-4.08; P<0.0001) and disruption (HR, 1.33; 95% CI, 1.05-1.68; P=0.02).
Discussion
TRANSLATE-ACS offered a unique opportunity to examine ADPri cessation patterns among acute MI patients within the first year post-PCI. Our study had several findings. First, despite guideline recommendations, >20% of patients stopped ADPri therapy within the first year post-MI. Second, in both unadjusted and adjusted analyses, patients discharged on prasugrel were more likely to stop ADPri therapy within 1 year than patients discharged on clopidogrel. Third, patients treated with DES were less likely to stop ADPri therapy, but still accounted for >50% of patients with early ADPri cessation. Fourth, early ADPri cessation was associated with a higher risk of downstream MACE, particularly among patients who received DES. Finally, although clinician-directed discontinuation was the most frequent patient-reported reason for ADPri cessation, only cessation that was attributed to interruption and disruption was significantly associated with increased risk of downstream MACE. The American College of Cardiology/American Heart Association practice guidelines provide a class I recommendation for ADPri therapy to ideally be administered for 12 months among all MI patients and for at least 12 months in those treated with DES. 11, 12 Nonetheless, we observed early cessation of ADPri treatment after MI in 21% of patients; of these, 54% had a DES. This finding suggests a persistent and significant discrepancy between guideline recommendations and real-world MI practice in the United States. The recently updated European Society of Cardiology guidelines for non-ST-elevation acute coronary syndrome (NSTE-ACS) 23 have acknowledged the inconsistency between guideline recommendations and clinical practice. The new European Society of Cardiology guidelines suggest a more individually tailored DAPT treatment duration, concluding that "…while Continuous variables are shown with the median (25th, 75th percentiles). Categorical variables are shown as percentages. Percentage calculated from all patients with a documented reason for cessation (47 patients missing reason for discontinuation were excluded from this analysis). ADPri indicates adenosine diphosphate receptor inhibitor; CABG, coronary artery bypass grafting; DES, drug-eluting stent; GI/GU, gastrointestinal/genitourinary; MI, myocardial infarction; PCI, percutaneous coronary intervention; PHQ-2, Patient Health Questionnaire-2; and STEMI, ST-segment-elevation myocardial infarction. a 1-year duration of DAPT in NSTE-ACS is recommended, based on individual patient ischemic and bleeding risk profiles, DAPT duration may be shortened (ie, 3-6 months) or extended (ie, up to 30 months) in selected patients if required." 11, 12 This new recommendation may actually be representative of how practice patterns are currently deployed. Recent studies have attempted to define the optimal length of DAPT after MI, with some results favoring shorter durations of therapy after DES implantation and others favoring longer durations. Yet, few of these studies have focused specifically on the post-MI population. 4, 5, 8 Previous studies examining a shorter duration of DAPT in patients with DES have been underpowered or the patients were given an older generation of DES, both of which may influence interpretation of results. In our study, we noticed differences in early cessation rates by stent type. Among patients receiving a BMS, we observed a cessation rate twice as high as those who received DES; this finding persisted in multivariable analysis. This was expected because guidelines recommend a minimum of 1 month of DAPT for patients with BMS, a minimum of 3 to 6 months of DAPT for patients with DES, and ideally 12 months of DAPT for both stent types. Notably, among 8427 patients who received a DES, 1349 (16%) stopped ADPri before 12 months. BMS were also more frequently used in patients who had higher bleeding risk. Importantly, early cessation of DAPT after DES implantation has been associated with increased MACE risk, which highlights the need to follow recommendations set forth by clinical guidelines. In our study, the association between early ADPri cessation and MACE did not change based on discharge ADPri type; however, among patients who received DES, early ADPri cessation was associated with an almost 2-fold increase in MACE.
We examined the incidence of early ADPri cessation in relation to the type of ADPri prescribed at discharge and type of implanted stent. The unadjusted difference in event rates was small (2%), but after multivariable adjustment, patients discharged on prasugrel were significantly more likely to have early ADPri cessation compared with those discharged on clopidogrel. The reasons for this difference could not be definitively established with our data, but the distribution of patient-reported reasons in Table 3 suggests that prasugrel discontinuation was more likely to be driven by provider recommendation and patient factors than clopidogrel discontinuation. Patients prescribed clopidogrel at discharge may be more likely to have planned surgical procedures, which could explain the higher rates of interruption compared with prasugrel-treated patients.
A unique feature of the TRANSLATE-ACS registry is that it tracks patient-reported reasons for ADPri cessation. Slightly >50% of MI patients with early ADPri cessation reported that their therapy discontinuation was recommended by their healthcare provider; this finding emphasizes the discrepancy between current provider practice and actual guideline recommendations. Table 2 suggests that patients recommended for ADPri discontinuation were with a lower risk, with fewer cardiovascular comorbidities than other cessation groups, and those who continued ADPri therapy. Bleeding risk may have been a concern for those who discontinued therapy because 10% of patients were also discharged on an oral anticoagulant; however, the need for anticoagulation is unlikely to be a major explanation for therapy discontinuation. Regardless of the precise reason for therapy cessation, our results suggest that there is room for improvement in the risk versus benefit evaluation of longterm antiplatelet therapy.
In the PARIS study, 11.5% of patients undergoing PCI discontinued ADPri therapy by 1 year, 4.6% had an interruption, and 9.8% had a disruption in therapy. 19 Our study, which focused on an MI population indicated for extended DAPT, showed similar proportions of early ADPri cessation; these estimates also mirrored previous smaller studies. [15] [16] [17] [18] Our study builds on the results from the PARIS study by actually categorizing the reasons for therapy disruption because of (1) medication side effects (including bleeding); (2) patient-driven factors; and (3) unknown reasons. We observed significant differences in patient characteristics among cessation reasons. Patients who stopped treatment because of patient factors were younger; more than one-third of these patients did not have health insurance, despite a greater likelihood of employment, compared with the other 2 groups. Patients who stopped treatment were also less likely to be married and to have graduated from high school compared with patients who stopped for other reasons.
Significantly, our results indicate that in both unadjusted and adjusted analyses there is an association between early cessation of ADPri and MACE. Compared with patients who continued ADPri therapy, cessation of ADPri because of discontinuation per healthcare provider was not associated with an increased risk of MACE. Nevertheless, therapy interruption or disruption was associated with a higher risk of MACE, a finding similar to results from the PARIS study. 5 These results indicate that even a short-term interruption in therapy or cessation because of medical side effects seems to be harmful to the patient.
Limitations
Our study has several limitations. First, the reasons for ADPri cessation were patient reported without independent medical record validation. If a patient indicated multiple reasons for ADPri cessation, then we classified the reason according to a predefined hierarchy. Second, potential consequences of early ADPri cessation may not have been evident at 1 year; however, longer-term outcomes could not be compared between groups. In the observational setting, all associations with outcomes may be confounded, despite rigorous risk adjustment. Finally, we did not have access to information on stent generation (eg, new versus old generation DES) because TRANSLATE-ACS does not record this information.
Conclusions
Despite guideline recommendations, we found that in contemporary United States practice, ≈1 in 5 acute MI patients stopped ADPri treatment within 1 year of discharge. Slightly >50% of discontinuations were driven by a physician recommendation, whereas ≈20% were driven by patient disruption. Early ADPri cessation was associated with an increased risk of MACE, but this association was most evident among those who interrupted treatment because of a procedure/surgery or had a disruption because of medication side effects. ADPri cessation was not associated with an increased risk of MACE among those who stopped therapy because of clinician or patient discretion.
